MoonLake Immunotherapeutics Class A Ordinary Shares MLTX · Stock Open MoonLake Immunotherapeutics Class A Ordinary Shares in new tab
MoonLake Immunotherapeutics Class A Ordinary Shares Analysis (MLTX)
Is MoonLake Immunotherapeutics Class A Ordinary Shares a good investment? MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX) is currently trading at 11.47 USD. Market analysts have a consensus price target of 28.54 USD. This suggests a potential upside from current levels.
Earnings Schedule: MoonLake Immunotherapeutics Class A Ordinary Shares is expected to release its next earnings report on Nov. 4, 2026. The market consensus estimate for Forward EPS is -3.33.
Investor FAQ
Does MoonLake Immunotherapeutics Class A Ordinary Shares pay a dividend?
No, it does not currently pay a dividend.
What asset class is MoonLake Immunotherapeutics Class A Ordinary Shares?
MoonLake Immunotherapeutics Class A Ordinary Shares is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 4, 2026. The company currently has a trailing EPS of -3.84.
Company Profile
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
Community Discussion